Philadelphia’s mass torts program, which has come under criticism in the last couple of years from conservative and defense-minded quarters, is ending the consolidation of pharmaceutical cases into reverse-bifurcation trials with the new year.
And on an interim basis, the Complex Litigation Center has ended the much longer-standing practice of consolidating asbestos cases into reverse-bifurcated trials with a comment period pending until Jan. 31 for the plaintiff asbestos and defense bars to comment on the practice of consolidating almost all asbestos cases into reverse-bifurcated trials.
